MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (146)	9/9/1997 5:56:00 PM
From: seminole	of 1826

Rick <I guess everyone agrees that the company is a wise investment, with or without acylfulvenes> Surprize, I also agree that MGI is valuable without acylfulvenes. I depend on the prospects of Salagen to protect my long term ivestment in MGI and acylfulvenes. Without Salagen's cash flow and MGI's strong balance sheet I would not be able to justify the risky postion I have taken in this stock. What about the biotech industry? Does anybody besides me see this market segment about to take off? Won't a strong biotech sector movement help MGI? I invest retirement money in Fidelity Select Biotech and its up 4+% this week as compared to only 10% for the year to date. I believe this is the start of a major move for this sector that has underperformed for the last few years. Perhaps, investor are rediscovering small companies with interesting drugs in clinical trails. Anyone know of a small company with an interesting drug in clinical trails that I could invest in? richard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next